Gabapentin (Neurontin) Dosing Recommendations
For neuropathic pain in adults with normal renal function, start gabapentin at 300 mg three times daily (or 100-300 mg at bedtime) and titrate by 100-300 mg every 1-7 days to a target of 1800 mg/day in three divided doses, with a maximum of 3600 mg/day if needed for adequate pain relief. 1, 2
Neuropathic Pain Dosing
Initial Titration Schedule
- Day 1: 100-300 mg at bedtime OR 100-300 mg three times daily
- Titration: Increase by 100-300 mg every 1-7 days as tolerated
- Target dose: 1800 mg/day (600 mg three times daily)
- Maximum dose: 3600 mg/day (1200 mg three times daily) 1, 2
The evidence strongly supports 1800 mg/day as the minimum effective dose for neuropathic pain. In postherpetic neuralgia, 32% of patients achieve substantial benefit (≥50% pain relief) at doses ≥1200 mg/day versus 17% with placebo (NNT 6.7). In painful diabetic neuropathy, 38% achieve substantial benefit versus 21% with placebo (NNT 5.9) 1. An adequate therapeutic trial requires 3-8 weeks for titration plus 2 weeks at maximum tolerated dose 1.
Critical Dosing Considerations
Gabapentin has nonlinear pharmacokinetics due to saturable absorption—bioavailability decreases from 60% at 900 mg/day to 27% at 4800 mg/day 2. This necessitates divided dosing three times daily with maximum 12-hour intervals between doses 2. Starting at lower doses and titrating gradually minimizes dose-dependent dizziness and sedation 1.
Real-world data reveals a significant problem: only 22.4% of patients with adequate renal function actually receive the minimum effective dose of 1800 mg/day 3. This represents systematic underdosing that compromises therapeutic outcomes.
Adjunctive Therapy for Partial Seizures
Adults and Children ≥12 Years
- Starting dose: 300 mg three times daily
- Titration: Increase as needed using 300-400 mg capsules or 600-800 mg tablets three times daily
- Effective dose: 900-1800 mg/day in three divided doses
- Maximum: 3600 mg/day (well-tolerated in clinical studies) 2
Pediatric Patients (Ages 3-12 Years)
- Starting dose: 10-15 mg/kg/day in three divided doses
- Titration period: Approximately 3 days
- Effective dose:
- Ages 5-12: 25-35 mg/kg/day in three divided doses
- Ages 3-4: 40 mg/kg/day in three divided doses 2
The higher dose requirement in younger children (ages 3-4) reflects their increased oral clearance normalized per body weight 2. Doses up to 50 mg/kg/day have been well-tolerated in long-term studies 2.
Renal Impairment Adjustments
Gabapentin is eliminated entirely by renal excretion as unchanged drug—dosage adjustment based on creatinine clearance is mandatory 2. Use the Cockcroft-Gault equation to estimate creatinine clearance:
Dosing by Creatinine Clearance
| CrCl (mL/min) | Total Daily Dose | Regimen Options |
|---|---|---|
| ≥60 | 900-3600 mg/day | 300-1200 mg TID |
| 30-59 | 400-1400 mg/day | 200-700 mg BID |
| 15-29 | 200-700 mg/day | 100-300 mg QD |
| <15 | 100-300 mg/day | 100-300 mg QD |
Post-hemodialysis supplemental doses: 125-350 mg after each 4-hour dialysis session 2
The half-life increases dramatically with renal impairment—from 6.5 hours (CrCl >60 mL/min) to 52 hours (CrCl <30 mL/min) 2, 4. In anuric patients, the half-life extends to 132 hours, reduced to 3.8 hours during dialysis 2.
Elderly Patients
Reduce doses in elderly patients due to age-related decline in renal function—apparent oral clearance decreases from 225 mL/min in patients <30 years to 125 mL/min in those >70 years 2. Adjust dosing based on creatinine clearance calculations, and consider slower titration schedules 1, 2.
Common Pitfalls and Safety Considerations
Adverse Events
- Most common: Dizziness (19%), somnolence (14%), peripheral edema (7%), gait disturbance (14%) 5
- Withdrawal rate: 11% versus 8.2% with placebo (NNH 30) 5
- Timing: Side effects typically occur at treatment onset and often subside within 10 days 6
Critical Safety Alerts
- Rhabdomyolysis risk: Monitor for unexplained myalgia, particularly with statin co-administration or renal impairment. Consider gabapentin cessation if CPK >3× upper limit of normal 7
- Drug interactions: Gabapentin has minimal drug interactions and does not alter levels of concomitant antiepileptic drugs 2
- Discontinuation: Taper gradually over minimum 1 week when stopping 2
Genetic Considerations
The OCT2 transporter variant (SLC22A2 c.808G>T) reduces CNS penetration 10-fold, potentially explaining treatment failures even at maximum doses 8. While routine genotyping is not yet standard practice, consider alternative therapies in patients who fail to respond to adequate gabapentin trials.